Cargando…

Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study

INTRODUCTION: Blood Pressure (BP) control is largely unsatisfied in End Stage Kidney Disease (ESKD) principally due to sodium retention. Peritoneal Dialysis (PD) is the most common type of home dialysis, using a peritoneal membrane to remove sodium, though sodium removal remains challenging. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Vecchi, Luigi, Bonomini, Mario, Palumbo, Roberto, Arduini, Arduino, Borrelli, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105985/
https://www.ncbi.nlm.nih.gov/pubmed/33964894
http://dx.doi.org/10.1186/s12882-021-02380-4
_version_ 1783689688156995584
author Vecchi, Luigi
Bonomini, Mario
Palumbo, Roberto
Arduini, Arduino
Borrelli, Silvio
author_facet Vecchi, Luigi
Bonomini, Mario
Palumbo, Roberto
Arduini, Arduino
Borrelli, Silvio
author_sort Vecchi, Luigi
collection PubMed
description INTRODUCTION: Blood Pressure (BP) control is largely unsatisfied in End Stage Kidney Disease (ESKD) principally due to sodium retention. Peritoneal Dialysis (PD) is the most common type of home dialysis, using a peritoneal membrane to remove sodium, though sodium removal remains challenging. METHODS: This is a case-study reporting two consecutive ESKD patients treated by a novel peritoneal PD solution with a mildly reduced sodium content (130 mmol/L) to treat hypertension. RESULTS: In the first case, a 78-year-old woman treated by Continuous Ambulatory PD (CAPD) with standard solution (three 4 h-dwells per day 1.36% glucose 132 mmol/L) showed resistant hypertension confirmed by ambulatory blood pressure monitoring (ABPM), reporting 24 h-BP: 152/81 mmHg, day-BP:151/83 mmHg and night-ABP: 153/75 mmHg, with inversion of the circadian systolic BP rhythm (1.01), despite use of three anti-hypertensives and a diuretic at adequate doses. No sign of hypervolemia was evident. We then switched from standard PD to low-sodium solution in all daily dwells. A six-months low-sodium CAPD enabled us to reduce diurnal (134/75 mmHg) and nocturnal BP (122/67 mmHg), restoring the circadian BP rhythm, with no change in ultrafiltration or residual diuresis. Diet and drug prescription were unmodified too. The second case was a 61-year-old woman in standard CAPD (three 5 h-dwells per day) suffering from hypertension confirmed by ABPM (mean 24 h-ABP: 139/84 mmHg; mean day-ABP:144/88 mmHg and mean night-ABP:124/70 mmHg). She was switched from 132-Na CAPD to 130-Na CAPD, not changing dialysis schedule. No fluid expansion was evident. During low-sodium CAPD, antihypertensive therapy (amlodipine 10 mg and Olmesartan 20 mg) has been reduced until complete suspension. After 6 months, we repeated ABPM showing a substantial reduction in mean 24 h-ABP (117/69 mmHg), mean diurnal ABP (119/75 mmHg) and mean nocturnal ABP (111/70 mmHg). Ultrafiltration and residual diuresis remained unmodified. No side effects were reported in either cases. CONCLUSIONS: This case-report study suggests that mild low-sodium CAPD might reduce BP in hypertensive ESKD patients.
format Online
Article
Text
id pubmed-8105985
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81059852021-05-10 Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study Vecchi, Luigi Bonomini, Mario Palumbo, Roberto Arduini, Arduino Borrelli, Silvio BMC Nephrol Case Report INTRODUCTION: Blood Pressure (BP) control is largely unsatisfied in End Stage Kidney Disease (ESKD) principally due to sodium retention. Peritoneal Dialysis (PD) is the most common type of home dialysis, using a peritoneal membrane to remove sodium, though sodium removal remains challenging. METHODS: This is a case-study reporting two consecutive ESKD patients treated by a novel peritoneal PD solution with a mildly reduced sodium content (130 mmol/L) to treat hypertension. RESULTS: In the first case, a 78-year-old woman treated by Continuous Ambulatory PD (CAPD) with standard solution (three 4 h-dwells per day 1.36% glucose 132 mmol/L) showed resistant hypertension confirmed by ambulatory blood pressure monitoring (ABPM), reporting 24 h-BP: 152/81 mmHg, day-BP:151/83 mmHg and night-ABP: 153/75 mmHg, with inversion of the circadian systolic BP rhythm (1.01), despite use of three anti-hypertensives and a diuretic at adequate doses. No sign of hypervolemia was evident. We then switched from standard PD to low-sodium solution in all daily dwells. A six-months low-sodium CAPD enabled us to reduce diurnal (134/75 mmHg) and nocturnal BP (122/67 mmHg), restoring the circadian BP rhythm, with no change in ultrafiltration or residual diuresis. Diet and drug prescription were unmodified too. The second case was a 61-year-old woman in standard CAPD (three 5 h-dwells per day) suffering from hypertension confirmed by ABPM (mean 24 h-ABP: 139/84 mmHg; mean day-ABP:144/88 mmHg and mean night-ABP:124/70 mmHg). She was switched from 132-Na CAPD to 130-Na CAPD, not changing dialysis schedule. No fluid expansion was evident. During low-sodium CAPD, antihypertensive therapy (amlodipine 10 mg and Olmesartan 20 mg) has been reduced until complete suspension. After 6 months, we repeated ABPM showing a substantial reduction in mean 24 h-ABP (117/69 mmHg), mean diurnal ABP (119/75 mmHg) and mean nocturnal ABP (111/70 mmHg). Ultrafiltration and residual diuresis remained unmodified. No side effects were reported in either cases. CONCLUSIONS: This case-report study suggests that mild low-sodium CAPD might reduce BP in hypertensive ESKD patients. BioMed Central 2021-05-08 /pmc/articles/PMC8105985/ /pubmed/33964894 http://dx.doi.org/10.1186/s12882-021-02380-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Vecchi, Luigi
Bonomini, Mario
Palumbo, Roberto
Arduini, Arduino
Borrelli, Silvio
Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study
title Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study
title_full Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study
title_fullStr Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study
title_full_unstemmed Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study
title_short Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study
title_sort mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105985/
https://www.ncbi.nlm.nih.gov/pubmed/33964894
http://dx.doi.org/10.1186/s12882-021-02380-4
work_keys_str_mv AT vecchiluigi mildsodiumreductioninperitonealdialysissolutionimproveshypertensioninendstagekidneydiseaseacasereportstudy
AT bonominimario mildsodiumreductioninperitonealdialysissolutionimproveshypertensioninendstagekidneydiseaseacasereportstudy
AT palumboroberto mildsodiumreductioninperitonealdialysissolutionimproveshypertensioninendstagekidneydiseaseacasereportstudy
AT arduiniarduino mildsodiumreductioninperitonealdialysissolutionimproveshypertensioninendstagekidneydiseaseacasereportstudy
AT borrellisilvio mildsodiumreductioninperitonealdialysissolutionimproveshypertensioninendstagekidneydiseaseacasereportstudy